A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9

Clinical Pharmacology and Therapeutics

Volumn 80, Issue 4, 2006, Pages 346-355

  Tham, Lai San ^a   Goh, Boon Cher ^a   Nafziger, Anne ^a   Guo, Jia Yi ^a   Wang, Ling Zhi ^a   Soong, Richie ^a   Lee, Soo Chin ^a  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ADULT; ALGORITHM; ARTICLE; ASIAN; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; FEMALE; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION MODEL; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION PROCESS;

ADULT; AGED; ALGORITHMS; ANALYSIS OF VARIANCE; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; ASIAN AMERICANS; COHORT STUDIES; FEMALE; HAPLOTYPES; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; WARFARIN;

EID: 33749239835     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clpt.2006.06.009     Document Type: Article

References (41)

1. Hirsh J., Dalen J.E., Anderson D.R., Poller L., Bussey H., Ansell J., et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 114 Suppl (1998) 445S-469S
2. Topic 200 generic drugs by units in 2004. Drug Topics Web site. March 7, 2005. Available from: URL: http://www.drugtopics.com/drugtopics/data/articlestandard/drugtopics/102 005/150069/article.pdf. Accessed April 19, 2006.
3. Hayes Jr. W.J. Control of Norway rats with residual rodenticide warfarin. Public Health Rep 65 (1950) 1537-1555
4. Crowther M.A., Ginsberg J.B., Kearon C., Harrison L., Johnson J., Massicotte M.P., et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 159 (1999) 46-48
5. Kovacs M.J., Rodger M., Anderson D.R., Morrow B., Kells G., Kovacs J., et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med 138 (2003) 714-719
6. Gedge J., Orme S., Hampton K.K., Channer K.S., and Hendra T.J. A comparison of a low-dose warfarin induction regimen with the modified Fennerty regimen in elderly inpatients. Age Ageing 29 (2000) 31-34
7. Poller L., Shiach C.R., MacCallum P.K., Johansen A.M., Munster A.M., Magalhaes A., et al. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet 352 (1998) 1505-1509
8. Fennerty A., Dolben J., Thomas P., Backhouse G., Bentley D.P., Campbell I.A., et al. Flexible induction dose regimen for warfarin and prediction of maintenance dose. BMJ 288 (1984) 1268-1270
9. Voora D., Eby C., Linder M.W., Milligan P.E., Bukaveckas B.L., McLeod H.L., et al. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost 93 (2005) 700-705
10. Gage B.F., Eby C., Milligan P.E., Banet G.A., Duncan J.R., and McLeod H.L. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 91 (2004) 87-94
11. Sconce E.A., Khan T.I., Wynne H.A., Avery P., Monkhouse L., King B.P., et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106 (2005) 2329-2333
12. Aquilante C.L., Langaee T.Y., Lopez L.M., Yarandi H.N., Tromberg J.S., Mohuczy D., et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther 79 (2006) 291-302
13. Kamali F., Khan T.I., King B.P., Frearson R., Kesteven P., Wood P., et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 75 (2004) 204-212
14. Scordo M.G., Pengo V., Spina E., Dahl M.L., Gusella M., and Padrini R. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72 (2002) 702-710
15. Taube J., Halsall D., and Baglin T. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96 (2000) 1816-1819
16. Takahashi H., Wilkinson G.R., Padrini R., and Echizen H. CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences. Clin Pharmacol Ther 75 (2004) 376-380
17. Zhao F., Loke C., Rankin S.C., Guo J.Y., Lee H.S., Wu T.S., et al. Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose. Clin Pharmacol Ther 76 (2004) 210-219
18. Hillman M.A., Wilke R.A., Yale S.H., Vidaillet H.J., Caldwell M.D., Glurich I., et al. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med Res 3 (2005) 137-145
19. Veenstra D.L., Blough D.K., Higashi M.K., Farin F.M., Srinouanprachan S., Rieder M.J., et al. CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes. Clin Pharmacol Ther 77 (2005) 353-364
20. Takahashi H., Wilkinson G.R., Caraco Y., Muszkat M., Kim R.B., Kashima T., et al. Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 73 (2003) 253-263
21. Furuya H., Fernandez-Salguero P., Gregory W., Taber H., Steward A., Gonzalez F.J., et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 5 (1995) 389-392
22. Rettie A.E., Haining R.L., Bajpai M., and Levy R.H. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res 35 (1999) 253-255
23. Voora D., McLeod H.L., Eby C., and Gage B.F. The pharmacogenetics of coumarin therapy. Pharmacogenomics 6 (2005) 503-513
24. Zainuddin Z., Teh L.K., Suhaimi A.W., and Ismail R. Malaysian Indians are genetically similar to Caucasians: CYP2C9 polymorphism. J Clin Pharm Ther 31 (2006) 187-191
25. Mushiroda T., Ohnishi Y., Saito S., Takahashi A., Kikuchi Y., Saito S., et al. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J Hum Genet 51 (2006) 249-253
26. Veenstra D.L., You J.H., Rieder M.J., Farin F.M., Wilkerson H.W., Blough D.K., et al. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 15 (2005) 687-691
27. Bae J.W., Kim H.K., Kim J.H., Yang S.I., Kim M.J., Jang C.G., et al. Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 60 (2005) 418-422
28. Chern H.D., Ueng T.H., Fu Y.P., and Cheng C.W. CYP2C9 polymorphism and warfarin sensitivity in Taiwan Chinese. Clin Chim Acta 367 (2006) 108-113
29. Lee S.C., Ng S.S., Oldenburg J., Chong P.Y., Rost S., Guo J.Y., et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin Pharmacol Ther 79 (2006) 197-205
30. Rieder M.J., Reiner A.P., Gage B.F., Nickerson D.A., Eby C.S., McLeod H.L., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352 (2005) 2285-2293
31. Wadelius M., Chen L.Y., Downes K., Ghori J., Hunt S., Eriksson N., et al. Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5 (2005) 262-270
32. Vecsler M., Loebstein R., Almog S., Kurnik D., Goldman B., Halkin H., et al. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 95 (2006) 205-211
33. Takahashi H., Wilkinson G.R., Nutescu E.A., Morita T., Ritchie M.D., Scordo M.G., et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16 (2006) 101-110
34. Tabrizi A.R., Zehnbauer B.A., Borecki I.B., McGrath S.D., Buchman T.G., and Freeman B.D. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin. J Am Coll Surg 194 (2002) 267-273
35. Loebstein R., Yonath H., Peleg D., Almog S., Rotenberg M., Lubetsky A., et al. Interindividual variability in sensitivity to warfarin-nature or nurture?. Clin Pharmacol Ther 70 (2001) 159-164
36. Imai J., Ieiri I., Mamiya K., Miyahara S., Furuumi H., Nanba E., et al. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus. Pharmacogenetics 10 (2000) 85-89
37. Kidd R.S., Curry T.B., Gallagher S., Edeki T., Blaisdell J., and Goldstein J.A. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11 (2001) 803-808
38. Higashi M.K., Veenstra D.L., Kondo L.M., Wittkowsky A.K., Srinouanprachanh S.L., Farin F.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287 (2002) 1690-1698
39. Leung A.Y., Chow H.C., Kwong Y.L., Lie A.K., Fung A.T., Chow W.H., et al. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 98 (2001) 2584-2587
40. Hunt C.M., Westerkam W.R., and Stave G.M. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44 (1992) 275-283
41. Hunt C.M., Watkins P.B., Saenger P., Stave G.M., Barlascini N., Watlington C.O., et al. Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clin Pharmacol Ther 51 (1992) 18-23